US09075V1026 - ADR
BIONTECH SE-ADR
NASDAQ:BNTX (10/29/2024, 5:57:51 PM)
After market: 114.01 0 (0%)114.01
+0.75 (+0.66%)
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,133 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ 55131
P: 4949613190840
CEO: Ugur Sahin
Employees: 6133
Website: https://www.biontech.com/
This drugmaker's lead candidate could become a top-selling cancer therapy.
MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the...
MAINZ, Deutschland, 21. Oktober 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 4. November...
Shares peaked near 62 in late 2021, but are now worth less than half of that.
Here you can normally see the latest stock twits on BNTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: